Whittier Trust Co. Sells 261 Shares of Edwards Lifesciences Co. (NYSE:EW)

Whittier Trust Co. cut its holdings in Edwards Lifesciences Co. (NYSE:EW) by 2.7% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 9,407 shares of the medical research company’s stock after selling 261 shares during the period. Whittier Trust Co.’s holdings in Edwards Lifesciences were worth $621,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. Park Avenue Securities LLC increased its holdings in shares of Edwards Lifesciences by 0.5% in the second quarter. Park Avenue Securities LLC now owns 23,484 shares of the medical research company’s stock worth $2,169,000 after purchasing an additional 108 shares during the last quarter. City State Bank grew its holdings in Edwards Lifesciences by 16.5% during the 2nd quarter. City State Bank now owns 917 shares of the medical research company’s stock valued at $85,000 after buying an additional 130 shares in the last quarter. Chapin Davis Inc. raised its holdings in shares of Edwards Lifesciences by 1.7% during the 1st quarter. Chapin Davis Inc. now owns 8,548 shares of the medical research company’s stock worth $817,000 after acquiring an additional 140 shares in the last quarter. Valley National Advisers Inc. boosted its position in shares of Edwards Lifesciences by 6.0% during the 1st quarter. Valley National Advisers Inc. now owns 2,677 shares of the medical research company’s stock valued at $255,000 after acquiring an additional 152 shares during the last quarter. Finally, Choreo LLC boosted its position in shares of Edwards Lifesciences by 4.1% during the 1st quarter. Choreo LLC now owns 3,840 shares of the medical research company’s stock valued at $367,000 after acquiring an additional 153 shares during the last quarter. 79.46% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction dated Wednesday, August 14th. The shares were sold at an average price of $66.08, for a total value of $330,400.00. Following the completion of the sale, the vice president now owns 46,936 shares in the company, valued at approximately $3,101,530.88. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction on Wednesday, August 14th. The stock was sold at an average price of $66.08, for a total value of $330,400.00. Following the transaction, the vice president now directly owns 46,936 shares in the company, valued at approximately $3,101,530.88. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, VP Daveen Chopra sold 1,250 shares of the company’s stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $69.95, for a total value of $87,437.50. Following the sale, the vice president now owns 29,333 shares of the company’s stock, valued at $2,051,843.35. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 16,250 shares of company stock worth $1,099,238 in the last three months. Corporate insiders own 1.29% of the company’s stock.

Edwards Lifesciences Stock Up 2.0 %

Shares of NYSE:EW opened at $70.63 on Thursday. The business’s 50 day moving average is $68.04 and its 200 day moving average is $78.71. The stock has a market cap of $42.56 billion, a P/E ratio of 30.44, a price-to-earnings-growth ratio of 2.83 and a beta of 1.13. Edwards Lifesciences Co. has a 52-week low of $58.93 and a 52-week high of $96.12. The company has a quick ratio of 2.87, a current ratio of 3.71 and a debt-to-equity ratio of 0.08.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Wednesday, July 24th. The medical research company reported $0.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.69 by $0.01. The business had revenue of $1.63 billion for the quarter, compared to the consensus estimate of $1.65 billion. Edwards Lifesciences had a return on equity of 22.35% and a net margin of 24.55%. The business’s revenue was up 6.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.66 EPS. Sell-side analysts predict that Edwards Lifesciences Co. will post 2.71 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on EW. Bank of America downgraded shares of Edwards Lifesciences from a “buy” rating to a “neutral” rating and decreased their price target for the company from $105.00 to $75.00 in a research note on Thursday, July 25th. JPMorgan Chase & Co. cut shares of Edwards Lifesciences from an “overweight” rating to a “neutral” rating and decreased their target price for the company from $105.00 to $72.00 in a research report on Thursday, July 25th. Daiwa America upgraded Edwards Lifesciences to a “strong-buy” rating in a research report on Wednesday, July 31st. Piper Sandler decreased their price objective on Edwards Lifesciences from $88.00 to $73.00 and set a “neutral” rating on the stock in a research report on Thursday, July 25th. Finally, Robert W. Baird cut Edwards Lifesciences from an “outperform” rating to a “neutral” rating and dropped their target price for the stock from $102.00 to $70.00 in a report on Thursday, July 25th. Fifteen research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Edwards Lifesciences currently has a consensus rating of “Hold” and a consensus price target of $75.81.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.